description
Powered by Eupheria Biotech
Quality Level
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
TCCATCCATGTTACCTGCAAGATGGTTTTGTTATTATAATTCCCATCCAAAGTACAGGAGATGCTCTGTTCCAGAGGAACAAGAACTCACTGATGAAGACCTGTGCTTGAGCAAAGCTAAGAAACAAGAACAAACTGTTGAGGAGAAGAAGAAGATGCCTATGGAAAATGAGAACCACCAGGTATTCAGTAATCCACCAAAGATCCTTACTGTTCAAGAAATGGCTGGATTGAATAACAAGACAATTGGATATGAGGGAATTCATAGCCCTAGTGTGCTTCCTTCTGGTGGAGAAGAAAGCAGATCACCATCTCTTCAACTTAAGCCTCTGGATTCCAGTGTTTTACAGTTTTCCAGTAAGTACAAATGGATCCTAGGTGAAGAACCGGTGGAGAAACGAAGAAGGCTCC
Ensembl | human accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Gene Information
human ... MORC4(79710)
General description
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Elisabeth Strack et al.
Clinical and translational medicine, 10(8), e239-e239 (2020-12-31)
Breast cancer is the leading cause of cancer-related deaths in women, demanding new treatment options. With the advent of immune checkpoint blockade, immunotherapy emerged as a treatment option. In addition to lymphocytes, tumor-associated macrophages exert a significant, albeit controversial, impact
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| EHU072321-50UG | 04061828372201 |
| EHU072321-20UG | 04061828611720 |